Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044538 · ClinicalTrials.gov registry record · Phase 2
Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT00044538 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 102 participants.
The verdict
NCT00044538, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
Lung cancer is among the most common cancers in the world and its incidence continues to increase. Chemotherapy for patients with Non-Small Cell Lung Cancer (NSCLC) has been under investigation for several decades and several new drugs with activity in NSCLC have been identified. These include the taxanes, which are among the most commonly used class of chemotherapy agents in clinical oncology today. The usefulness of the taxanes is limited by the development of tumor resistance to these agents. This phase II trial with BAY 59-8862 will be conducted to determine the anti-tumor efficacy of BAY 59-8862 in taxane-resistant NSCLC.
Interventions
- DRUG BAY59-8862 (Cytotoxic Taxane)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2001-12 |
| Est. Completion | 2004-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044538
The ClinicalTrials.gov registry entry for NCT00044538 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAY59-8862 (Cytotoxic Taxane) is the first listed.
NCT00044538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044538 about?
NCT00044538 is a clinical study titled "Evaluation of BAY 59-8862 in Taxane Resistant Non-Small Cell Lung Cancer Patients". Lung cancer is among the most common cancers in the world and its incidence continues to increase. Chemotherapy for patients with Non-Small Cell Lung Cancer (NSCLC) has been under investigation for several decades and several new drugs with activity in NSCLC have been identified. These include the t...
What is the current status of trial NCT00044538?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2001-12. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00044538?
The interventions under investigation include: BAY59-8862 (Cytotoxic Taxane) (DRUG).
Who is sponsoring clinical trial NCT00044538?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.